Cargando…

Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials

PURPOSE: The objective of this study was to examine the psychometric properties of the St. George’s Respiratory Questionnaire (SGRQ) in patients with chronic obstructive pulmonary disease (COPD) using Rasch measurement theory (RMT) analyses. MATERIALS AND METHODS: RMT analysis was conducted on the b...

Descripción completa

Detalles Bibliográficos
Autores principales: Loubert, Angely, Regnault, Antoine, Meunier, Juliette, Gutzwiller, Florian S, Regnier, Stéphane A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490086/
https://www.ncbi.nlm.nih.gov/pubmed/32982203
http://dx.doi.org/10.2147/COPD.S261919
_version_ 1783581977950027776
author Loubert, Angely
Regnault, Antoine
Meunier, Juliette
Gutzwiller, Florian S
Regnier, Stéphane A
author_facet Loubert, Angely
Regnault, Antoine
Meunier, Juliette
Gutzwiller, Florian S
Regnier, Stéphane A
author_sort Loubert, Angely
collection PubMed
description PURPOSE: The objective of this study was to examine the psychometric properties of the St. George’s Respiratory Questionnaire (SGRQ) in patients with chronic obstructive pulmonary disease (COPD) using Rasch measurement theory (RMT) analyses. MATERIALS AND METHODS: RMT analysis was conducted on the baseline SGRQ data from five multi-national, Phase III randomized trials investigating a fixed-dose combination of a long-acting β2-agonist and a long-acting muscarinic antagonist in COPD patients. Analysis was performed for the SGRQ “Symptoms” and “Activity” domains. An exploratory analysis was also conducted using the different specific symptoms as defined in the reconceptualization of the SGRQ “Symptoms” domain. Differential item functioning (DIF) analysis was performed for geographical regions on the “Activity” domain, in order to explore cross-cultural validity of the SGRQ. RESULTS: Overall, the SGRQ “Activity” domain showed good measurement property, but two items (“Sitting or lying still making feel breathless” and “Playing sports or game making feel breathless”) showed very high fit residuals. The SGRQ “Symptoms” domain demonstrated good targeting; however, two items showed disordered thresholds (“Coughed” and “Brought up phlegm”). In an exploratory RMT analysis, measures for “Cough and Sputum”, “Breathing difficulties” or “Wheezing attacks” showed unsatisfactory measurement properties with poor reliability (person separation index = 0.35, 0.66 and 0.16, respectively) and targeting issues. The examination of cross-cultural performances of the SGRQ “Activity” items showed a great variability in the responses to these items in different global regions. CONCLUSION: Our results indicated that SGRQ may not be an appropriate instrument to measure symptom severity or activity limitations in patients with COPD. Hence, there is a need to develop other relevant PRO instruments that can be used in conjunction with SGRQ to provide a holistic assessment of the health status of COPD patients in clinical research.
format Online
Article
Text
id pubmed-7490086
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74900862020-09-24 Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials Loubert, Angely Regnault, Antoine Meunier, Juliette Gutzwiller, Florian S Regnier, Stéphane A Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: The objective of this study was to examine the psychometric properties of the St. George’s Respiratory Questionnaire (SGRQ) in patients with chronic obstructive pulmonary disease (COPD) using Rasch measurement theory (RMT) analyses. MATERIALS AND METHODS: RMT analysis was conducted on the baseline SGRQ data from five multi-national, Phase III randomized trials investigating a fixed-dose combination of a long-acting β2-agonist and a long-acting muscarinic antagonist in COPD patients. Analysis was performed for the SGRQ “Symptoms” and “Activity” domains. An exploratory analysis was also conducted using the different specific symptoms as defined in the reconceptualization of the SGRQ “Symptoms” domain. Differential item functioning (DIF) analysis was performed for geographical regions on the “Activity” domain, in order to explore cross-cultural validity of the SGRQ. RESULTS: Overall, the SGRQ “Activity” domain showed good measurement property, but two items (“Sitting or lying still making feel breathless” and “Playing sports or game making feel breathless”) showed very high fit residuals. The SGRQ “Symptoms” domain demonstrated good targeting; however, two items showed disordered thresholds (“Coughed” and “Brought up phlegm”). In an exploratory RMT analysis, measures for “Cough and Sputum”, “Breathing difficulties” or “Wheezing attacks” showed unsatisfactory measurement properties with poor reliability (person separation index = 0.35, 0.66 and 0.16, respectively) and targeting issues. The examination of cross-cultural performances of the SGRQ “Activity” items showed a great variability in the responses to these items in different global regions. CONCLUSION: Our results indicated that SGRQ may not be an appropriate instrument to measure symptom severity or activity limitations in patients with COPD. Hence, there is a need to develop other relevant PRO instruments that can be used in conjunction with SGRQ to provide a holistic assessment of the health status of COPD patients in clinical research. Dove 2020-09-08 /pmc/articles/PMC7490086/ /pubmed/32982203 http://dx.doi.org/10.2147/COPD.S261919 Text en © 2020 Loubert et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Loubert, Angely
Regnault, Antoine
Meunier, Juliette
Gutzwiller, Florian S
Regnier, Stéphane A
Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials
title Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials
title_full Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials
title_fullStr Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials
title_full_unstemmed Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials
title_short Is the St. George’s Respiratory Questionnaire an Appropriate Measure of Symptom Severity and Activity Limitations for Clinical Trials in COPD? Analysis of Pooled Data from Five Randomized Clinical Trials
title_sort is the st. george’s respiratory questionnaire an appropriate measure of symptom severity and activity limitations for clinical trials in copd? analysis of pooled data from five randomized clinical trials
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490086/
https://www.ncbi.nlm.nih.gov/pubmed/32982203
http://dx.doi.org/10.2147/COPD.S261919
work_keys_str_mv AT loubertangely isthestgeorgesrespiratoryquestionnaireanappropriatemeasureofsymptomseverityandactivitylimitationsforclinicaltrialsincopdanalysisofpooleddatafromfiverandomizedclinicaltrials
AT regnaultantoine isthestgeorgesrespiratoryquestionnaireanappropriatemeasureofsymptomseverityandactivitylimitationsforclinicaltrialsincopdanalysisofpooleddatafromfiverandomizedclinicaltrials
AT meunierjuliette isthestgeorgesrespiratoryquestionnaireanappropriatemeasureofsymptomseverityandactivitylimitationsforclinicaltrialsincopdanalysisofpooleddatafromfiverandomizedclinicaltrials
AT gutzwillerflorians isthestgeorgesrespiratoryquestionnaireanappropriatemeasureofsymptomseverityandactivitylimitationsforclinicaltrialsincopdanalysisofpooleddatafromfiverandomizedclinicaltrials
AT regnierstephanea isthestgeorgesrespiratoryquestionnaireanappropriatemeasureofsymptomseverityandactivitylimitationsforclinicaltrialsincopdanalysisofpooleddatafromfiverandomizedclinicaltrials